Literature DB >> 18558793

Ethnic differences in the risks of adverse reactions to drugs used in the treatment of psychoses and depression: a systematic review and meta-analysis.

Sara Ormerod1, Sarah E McDowell, Jamie J Coleman, Robin E Ferner.   

Abstract

BACKGROUND: Factors such as age, sex and disease state alter a patient's susceptibility to adverse drug reactions (ADRs). Ethnicity may also alter the risk of an ADR.
OBJECTIVE: To review the evidence for ethnic differences in susceptibility to adverse reactions to drugs used to treat psychoses and depression. DATA SOURCES: We searched MEDLINE (from 1951), EMBASE (from 1974), and PsycINFO (from 1950) to March 2006. STUDY SELECTION: Studies were included if there was a mention of ethnicity, ethnic or racial groups and a description of a procedure to investigate ADRs specifically or a description of ADRs that were a result of drugs in therapeutic use. Studies selected by any two reviewers were retained if they referred to drugs used in the treatment of psychoses and related disorders or antidepressant drugs. Of 124 studies describing ADRs to antipsychotics or antidepressants, 51 reported data from different ethnic groups. DATA EXTRACTION: Data were extracted independently from those studies selected for inclusion by two reviewers, using a standard data extraction form. Studies were assessed for bias in order to determine the quality of the study. DATA SYNTHESIS: In a pooled analysis of patients treated with antipsychotics, the relative risk (RR) of tardive dyskinesia in Black compared with White patients was 1.03 (95% CI 0.85, 1.24); the RR of extrapyramidal symptoms in East Asian compared with non-East Asian patients was 1.38 (95% CI 1.11, 1.72); the RR of hyperglycaemia in Black compared with non-Black patients was 1.55 (95% CI 0.95, 2.53); and the RR of diabetes mellitus in non-White compared with White patients was 1.35 (95% CI 0.95, 1.92). It was impossible to perform pooled analysis of data from studies investigating antidepressants due to insufficient data.
CONCLUSIONS: We found limited evidence of ethnic differences in the risk of ADRs. The clinical implications of these results remain unclear because of confounding factors. Further progress will require improved recruitment of patients from different ethnic groups and an established consensus on how to define ethnicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18558793     DOI: 10.2165/00002018-200831070-00005

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  82 in total

1.  Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.

Authors:  B R Basson; B J Kinon; C C Taylor; K A Szymanski; J A Gilmore; G D Tollefson
Journal:  J Clin Psychiatry       Date:  2001-04       Impact factor: 4.384

2.  Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates.

Authors:  J Steven Lamberti; G Oana Costea; David Olson; John F Crilly; Kumar Maharaj; Xin Tu; Adrienne Groman; Marci B Dietz; Margaret P Bushey; Telva Olivares; Karen Wiener
Journal:  J Clin Psychiatry       Date:  2005-07       Impact factor: 4.384

3.  Neuroleptic dosage for Asians: a failure to replicate.

Authors:  J J Sramek; M A Sayles; G M Simpson
Journal:  Am J Psychiatry       Date:  1986-04       Impact factor: 18.112

4.  Factors associated with medication adherence in African American and white patients with bipolar disorder.

Authors:  David E Fleck; Paul E Keck; Kimberly B Corey; Stephen M Strakowski
Journal:  J Clin Psychiatry       Date:  2005-05       Impact factor: 4.384

5.  Pathways to care and ethnicity. 1: Sample characteristics and compulsory admission. Report from the AESOP study.

Authors:  C Morgan; R Mallett; G Hutchinson; H Bagalkote; K Morgan; P Fearon; P Dazzan; J Boydell; K McKenzie; G Harrison; R Murray; P Jones; T Craig; J Leff
Journal:  Br J Psychiatry       Date:  2005-04       Impact factor: 9.319

6.  Changes in negative symptoms and the risk of tardive dyskinesia: a longitudinal study. UK700 Group.

Authors:  J van Os; E Walsh; E van Horn; T Tattan; R Bale; S G Thompson
Journal:  Acta Psychiatr Scand       Date:  2000-04       Impact factor: 6.392

Review 7.  Will tomorrow's medicines work for everyone?

Authors:  Sarah K Tate; David B Goldstein
Journal:  Nat Genet       Date:  2004-11       Impact factor: 38.330

Review 8.  Frequency of new-onset diabetes mellitus and use of antipsychotic drugs among Central Texas veterans.

Authors:  Jamie C Barner; Jason Worchel; Min Yang
Journal:  Pharmacotherapy       Date:  2004-11       Impact factor: 4.705

9.  Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.

Authors:  D V Jeste; M P Caligiuri; J S Paulsen; R K Heaton; J P Lacro; M J Harris; A Bailey; R L Fell; L A McAdams
Journal:  Arch Gen Psychiatry       Date:  1995-09

10.  Incidence and correlates of tardive dyskinesia in first episode of schizophrenia.

Authors:  M H Chakos; J M Alvir; M G Woerner; A Koreen; S Geisler; D Mayerhoff; S Sobel; J M Kane; M Borenstein; J A Lieberman
Journal:  Arch Gen Psychiatry       Date:  1996-04
View more
  10 in total

1.  Physical Health Outcomes in Preschoolers with Prior Authorization for Antipsychotics.

Authors:  Yu-Jung Wei; Xinyue Liu; Nikhil Rao; Marie McPherson; Mary Beth Jones; Regina Bussing; Almut G Winterstein
Journal:  J Child Adolesc Psychopharmacol       Date:  2017-07-14       Impact factor: 2.576

2.  Exploring Biologic Predictors Response Disparities to Atypical Antipsychotics among Blacks: A Quasi-Systematic Review.

Authors:  Rebecca N Jerome; Jill M Pulley; Nila A Sathe; Shanthi Krishnaswami; Alyssa B Dickerson; Katherine J Worley; Consuelo H Wilkins
Journal:  Ethn Dis       Date:  2020-04-02       Impact factor: 1.847

3.  The impact of self-identified race on epidemiologic studies of gene expression.

Authors:  Sunita Sharma; Amy Murphy; Judie Howrylak; Blanca Himes; Michael H Cho; Jen-Hwa Chu; Gary M Hunninghake; Anne Fuhlbrigge; Barbara Klanderman; John Ziniti; Jody Senter-Sylvia; Andy Liu; Stanley J Szefler; Robert Strunk; Mario Castro; Nadia N Hansel; Gregory B Diette; Becky M Vonakis; N Franklin Adkinson; Vincent J Carey; Benjamin A Raby
Journal:  Genet Epidemiol       Date:  2011-02       Impact factor: 2.135

4.  Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.

Authors:  Koen Demyttenaere; Johan Detraux; Giorgio Racagni; Kristof Vansteelandt
Journal:  CNS Drugs       Date:  2019-06       Impact factor: 5.749

Review 5.  Do we need to consider ethno-cultural variation in the use of atypical antipsychotics for Asian patients with major depressive disorder?

Authors:  Changsu Han; Chi-Un Pae
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

6.  A culturally competent education program to increase understanding about medicines among ethnic minorities.

Authors:  Lourdes Cantarero-Arévalo; Dumoue Kassem; Janine Marie Traulsen
Journal:  Int J Clin Pharm       Date:  2014-09-07

7.  Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.

Authors:  Virginia L Stauffer; Jennifer L Sniadecki; Kevin W Piezer; Jennifer Gatz; Sara Kollack-Walker; Vicki Poole Hoffmann; Robert Conley; Todd Durell
Journal:  BMC Psychiatry       Date:  2010-11-03       Impact factor: 3.630

Review 8.  A consensus statement for safety monitoring guidelines of treatments for major depressive disorder.

Authors:  Seetal Dodd; Gin S Malhi; John Tiller; Isaac Schweitzer; Ian Hickie; Jon Paul Khoo; Darryl L Bassett; Bill Lyndon; Philip B Mitchell; Gordon Parker; Paul B Fitzgerald; Marc Udina; Ajeet Singh; Steven Moylan; Francesco Giorlando; Carolyn Doughty; Christopher G Davey; Michael Theodoros; Michael Berk
Journal:  Aust N Z J Psychiatry       Date:  2011-09       Impact factor: 5.744

9.  Drug-induced Extrapyramidal Symptoms Scale (DIEPSS) Serbian Language version: Inter-rater and Test-retest Reliability.

Authors:  Ami Peljto; Ljubica Zamurovic; Milica Pejovic Milovancevic; Branko Aleksic; Dusica Lecic Tosevski; Toshiya Inada
Journal:  Sci Rep       Date:  2017-08-14       Impact factor: 4.379

Review 10.  Antipsychotic Polypharmacy: A Dirty Little Secret or a Fashion?

Authors:  Shih-Ku Lin
Journal:  Int J Neuropsychopharmacol       Date:  2020-02-01       Impact factor: 5.176

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.